SIMILAR PATTERNS OF AMINO ACIDS FOR 1OPJ_A_STIA3_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 VAL A 64 PHE A 82 LEU A 133 ALA A 143	None	0.47A	1opjA-1h4lA: 16.4	1opjA-1h4lA: 24.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 GLU A 236 MET A 240 VAL A 249 THR A 266 LEU A 321	None	0.56A	1opjA-1k9aA: 30.9	1opjA-1k9aA: 30.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 GLU A 236 MET A 240 VAL A 249 THR A 266	None	0.56A	1opjA-1k9aA: 30.9	1opjA-1k9aA: 30.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.67A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.60A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818	None	0.67A	1opjA-1rjbA: 32.5	1opjA-1rjbA: 35.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 595 VAL A 603 ALA A 621 GLU A 640 VAL A 654 THR A 670 LEU A 799 ASP A 810	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-4.3A) STI A 3 (-3.2A) STI A 3 (-4.4A) STI A 3 (-3.9A)	0.55A	1opjA-1t46A: 34.0	1opjA-1t46A: 36.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 344 VAL A 352 ALA A 367 GLU A 386 MET A 390 VAL A 399 LEU A 468	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) None None None STU A 100 (-4.5A)	0.60A	1opjA-1u59A: 29.8	1opjA-1u59A: 38.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 15 VAL A 23 ALA A 36 GLU A 55 VAL A 68 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) None HYM A 400 (-4.8A) HYM A 400 (-4.5A)	0.74A	1opjA-1zltA: 20.9	1opjA-1zltA: 24.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 26 VAL A 34 ALA A 47 GLU A 65 PHE A 100 LEU A 155 ASP A 166	STU A1301 (-4.2A) STU A1301 (-4.8A) STU A1301 (-3.6A) None STU A1301 (-4.5A) STU A1301 ( 4.8A) None	0.72A	1opjA-2bujA: 22.7	1opjA-2bujA: 23.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 VAL X 25 ALA X 37 GLU X 54 MET X 58 VAL X 67 THR X 82 LEU X 137 ALA X 147	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 ( 4.4A) None None STU X 902 (-4.1A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.66A	1opjA-2dq7X: 31.7	1opjA-2dq7X: 44.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 162 VAL A 170 ALA A 184 GLU A 201 ILE A 208 ALA A 319	None	0.59A	1opjA-2eu9A: 13.7	1opjA-2eu9A: 23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 162 VAL A 170 ALA A 184 GLU A 201 VAL A 220 LEU A 290 ALA A 319	None	0.56A	1opjA-2eu9A: 13.7	1opjA-2eu9A: 23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 VAL A 323 THR A 338 LEU A 393 ALA A 403	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 (-3.1A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.85A	1opjA-2h8hA: 29.7	1opjA-2h8hA: 28.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 VAL A 323 THR A 338 PHE A 340	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-4.2A)	0.67A	1opjA-2hckA: 29.4	1opjA-2hckA: 30.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 ALA A 271 MET A 292 VAL A 301 THR A 316 PHE A 318 ALA A 381 ASP A 382	1BM A 499 ( 3.7A) 1BM A 499 (-3.6A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) 1BM A 499 ( 3.7A) 1BM A 499 (-4.4A)	0.89A	1opjA-2hk5A: 26.5	1opjA-2hk5A: 46.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 GLU A 288 MET A 292 VAL A 301 THR A 316 PHE A 318	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A)	0.63A	1opjA-2hk5A: 26.5	1opjA-2hk5A: 46.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 VAL A 259 ALA A 271 MET A 292 VAL A 301 THR A 316 PHE A 318 LEU A 371 ALA A 381	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 ( 3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.88A	1opjA-2hk5A: 26.5	1opjA-2hk5A: 46.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	GLU A 286 MET A 290 ILE A 293 VAL A 299 THR A 315 PHE A 317 ALA A 380 ASP A 381	GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.75A	1opjA-2hz0A: 34.5	1opjA-2hz0A: 97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 248 VAL A 256 ALA A 269 GLU A 286 MET A 290 ILE A 293 VAL A 299 THR A 315 PHE A 317 ALA A 380	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) GIN A 600 (-3.1A)	0.62A	1opjA-2hz0A: 34.5	1opjA-2hz0A: 97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 248 VAL A 256 ALA A 269 GLU A 286 MET A 290 VAL A 299 THR A 315 PHE A 317 LEU A 370 ALA A 380	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.54A	1opjA-2hz0A: 34.5	1opjA-2hz0A: 97.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	VAL A 436 ALA A 452 GLU A 471 MET A 475 VAL A 484 LEU A 553	4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 ( 4.6A) None None 4ST A1687 (-4.4A)	0.65A	1opjA-2j0jA: 31.6	1opjA-2j0jA: 20.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 GLU A 51 VAL A 64 PHE A 82 LEU A 134 ALA A 144	None	0.64A	1opjA-2jgzA: 16.3	1opjA-2jgzA: 28.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 251 VAL A 259 ALA A 271 GLU A 288 MET A 292 VAL A 301 THR A 316 LEU A 371 ALA A 381 ASP A 382	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A)	0.66A	1opjA-2og8A: 26.1	1opjA-2og8A: 45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 ALA A 614 GLU A 633 MET A 637 VAL A 647 THR A 663 ASP A 796	None	0.92A	1opjA-2ogvA: 22.0	1opjA-2ogvA: 38.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 GLU A 633 MET A 637 VAL A 647 THR A 663 LEU A 785	None	0.85A	1opjA-2ogvA: 22.0	1opjA-2ogvA: 38.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 487 VAL A 495 ALA A 515 GLU A 534 MET A 538 ILE A 541 LEU A 633 ALA A 643	None	0.60A	1opjA-2psqA: 31.3	1opjA-2psqA: 35.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 THR A 265 PHE A 267 LEU A 328 ALA A 338	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 (-4.3A) ADE A 488 (-4.3A) ADE A 488 (-4.4A) None	0.69A	1opjA-2qluA: 24.2	1opjA-2qluA: 24.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 ALA A 749 VAL A 781 THR A 796 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.0A) GW7 A 1 (-4.2A)	0.72A	1opjA-2r4bA: 28.8	1opjA-2r4bA: 36.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 68 VAL A 76 ALA A 92 VAL A 125 PHE A 143 LEU A 194	STU A 1 (-3.8A) None STU A 1 (-3.3A) None STU A 1 (-4.6A) STU A 1 (-4.6A)	0.51A	1opjA-2z7rA: 21.2	1opjA-2z7rA: 26.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.51A	1opjA-2z8cA: 28.8	1opjA-2z8cA: 38.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 VAL A 303 THR A 319 PHE A 321 ALA A 384 ASP A 385	None	0.73A	1opjA-2zv7A: 25.4	1opjA-2zv7A: 46.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 VAL A 303 THR A 319 PHE A 321 LEU A 374 ALA A 384	None	0.87A	1opjA-2zv7A: 25.4	1opjA-2zv7A: 46.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 ALA A 515 GLU A 534 MET A 538 ILE A 541	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None None	0.64A	1opjA-3b2tA: 24.3	1opjA-3b2tA: 39.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 MET A 538 ILE A 541 LEU A 633 ALA A 643	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None M33 A1996 (-4.5A) None	0.68A	1opjA-3b2tA: 24.3	1opjA-3b2tA: 39.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 GLU A 531 ILE A 538 LEU A 630 ALA A 640	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.63A	1opjA-3c4fA: 31.6	1opjA-3c4fA: 39.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 MET A 535 ILE A 538 LEU A 630 ALA A 640	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) C4F A 1 ( 3.7A) None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.63A	1opjA-3c4fA: 31.6	1opjA-3c4fA: 39.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 GLU A 236 MET A 240 VAL A 249 THR A 266 LEU A 321	None	0.56A	1opjA-3d7uA: 26.5	1opjA-3d7uA: 44.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 GLU A 236 MET A 240 VAL A 249 THR A 266	None	0.56A	1opjA-3d7uA: 26.5	1opjA-3d7uA: 44.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 663 GLU A 682 MET A 686 VAL A 695 PHE A 713 ASP A 776	IHZ A1001 (-3.3A) IHZ A1001 (-3.8A) IHZ A1001 (-3.5A) IHZ A1001 ( 4.9A) None IHZ A1001 (-4.8A)	0.73A	1opjA-3dkoA: 30.2	1opjA-3dkoA: 35.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 647 ALA A 663 GLU A 682 MET A 686 VAL A 695 PHE A 713	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 (-3.8A) IHZ A1001 (-3.5A) IHZ A1001 ( 4.9A) None	0.68A	1opjA-3dkoA: 30.2	1opjA-3dkoA: 35.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 833 VAL A 841 ALA A 859 GLU A 878 ILE A 885 VAL A 892 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.7A) None	0.70A	1opjA-3hngA: 32.8	1opjA-3hngA: 34.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 841 ALA A 859 GLU A 878 ILE A 885 VAL A 892 LEU A1029 ASP A1040	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.7A) None None	0.81A	1opjA-3hngA: 32.8	1opjA-3hngA: 34.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	VAL A 67 ALA A 80 MET A 104 VAL A 113 ALA A 192 ASP A 193	None	0.63A	1opjA-3iecA: 22.4	1opjA-3iecA: 25.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	VAL A 67 ALA A 80 MET A 104 VAL A 113 LEU A 182 ALA A 192	None	0.73A	1opjA-3iecA: 22.4	1opjA-3iecA: 25.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 33 ALA A 46 GLU A 66 VAL A 79 PHE A 105 LEU A 156 ALA A 166	None	0.64A	1opjA-3mi9A: 22.6	1opjA-3mi9A: 26.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 49 VAL A 57 ALA A 70 GLU A 91 VAL A 104 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None XFE A 351 (-4.6A)	0.74A	1opjA-3mvjA: 20.6	1opjA-3mvjA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	VAL A 37 ALA A 49 GLU A 69 VAL A 82 PHE A 100 LEU A 151 ALA A 161	ADP A 314 (-4.0A) ADP A 314 (-3.5A) None None ADP A 314 ( 4.3A) ADP A 314 (-4.6A) None	0.78A	1opjA-3nizA: 22.5	1opjA-3nizA: 26.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 88 VAL A 96 ALA A 109 GLU A 130 MET A 134 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) None None	0.57A	1opjA-3nuuA: 22.5	1opjA-3nuuA: 25.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 423 VAL A 431 ALA A 443 MET A 464 VAL A 473 THR A 489 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None PP2 A 1 (-3.3A) PP2 A 1 (-4.6A)	0.66A	1opjA-3sxsA: 31.0	1opjA-3sxsA: 41.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 GLU A 531 MET A 535 ILE A 538 LEU A 630 ALA A 640	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) None 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.62A	1opjA-3tt0A: 30.5	1opjA-3tt0A: 34.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 LEU A1035	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None 4TT A2001 (-4.5A) 4TT A2001 (-4.8A)	0.68A	1opjA-3vidA: 29.9	1opjA-3vidA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 VAL A 848 ALA A 866 ILE A 892 VAL A 899 PHE A 918 LEU A1035 ASP A1046	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None 4TT A2001 (-4.5A) 4TT A2001 (-4.8A) None	0.77A	1opjA-3vidA: 29.9	1opjA-3vidA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 GLU A 885 VAL A 899 PHE A 918 LEU A1035	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.7A) None LEV A1201 (-4.7A) LEV A1201 (-4.8A)	0.62A	1opjA-3wzdA: 30.8	1opjA-3wzdA: 37.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 ILE A 892 VAL A 899 PHE A 918 LEU A1035	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None None LEV A1201 (-4.7A) LEV A1201 (-4.8A)	0.64A	1opjA-3wzdA: 30.8	1opjA-3wzdA: 37.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 GLU A 50 VAL A 63 PHE A 81 LEU A 132	38R A 350 ( 4.8A) 38R A 350 (-3.4A) 38R A 350 ( 4.8A) 38R A 350 ( 4.9A) 38R A 350 (-4.2A) 38R A 350 (-4.3A)	0.49A	1opjA-3zduA: 22.3	1opjA-3zduA: 28.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 633 ALA A 649 GLU A 668 MET A 672 THR A 697 PHE A 699	None	0.75A	1opjA-3zfxA: 31.5	1opjA-3zfxA: 40.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 LEU A1035 ASP A1046	B49 A2000 (-3.7A) B49 A2000 (-3.5A) None None B49 A2000 ( 4.6A) B49 A2000 (-4.4A) B49 A2000 (-4.5A) None	0.69A	1opjA-4agdA: 32.4	1opjA-4agdA: 35.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 LEU A1035	B49 A2000 (-3.7A) None B49 A2000 (-3.5A) None None B49 A2000 ( 4.6A) B49 A2000 (-4.4A) B49 A2000 (-4.5A)	0.68A	1opjA-4agdA: 32.4	1opjA-4agdA: 35.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 42 VAL A 50 ALA A 63 VAL A 94 LEU A 164 ALA A 174	XZN A1317 (-3.6A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.61A	1opjA-4bc6A: 21.2	1opjA-4bc6A: 28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 42 VAL A 50 ALA A 63 VAL A 94 PHE A 112 ALA A 174	XZN A1317 (-3.6A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.5A) XZN A1317 ( 4.3A)	0.50A	1opjA-4bc6A: 21.2	1opjA-4bc6A: 28.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 616 VAL A 624 ALA A 653 GLU A 672 MET A 676 THR A 701 LEU A 773 ALA A 783 ASP A 784	None DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.6A) DI1 A1000 (-4.5A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A)	0.70A	1opjA-4ckrA: 32.1	1opjA-4ckrA: 37.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 663 VAL A 671 ALA A 684 GLU A 705 VAL A 721 LEU A 789 ALA A 799	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.69A	1opjA-4crsA: 15.9	1opjA-4crsA: 26.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 VAL A 863 ALA A 880 GLU A 898 VAL A 911 LEU A 983	IZA A2001 (-3.7A) None IZA A2001 (-3.4A) None None IZA A2001 ( 4.7A)	0.70A	1opjA-4gl9A: 19.7	1opjA-4gl9A: 34.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 828 VAL A 836 ALA A 853 GLU A 871 VAL A 884 LEU A 956 ALA A 966	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) None None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.58A	1opjA-4hviA: 29.5	1opjA-4hviA: 35.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 ALA A 506 GLU A 525 MET A 529 ILE A 532 LEU A 624 ALA A 634	ACP A 801 (-3.8A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None ACP A 801 (-4.4A) None	0.75A	1opjA-4k33A: 25.3	1opjA-4k33A: 37.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 VAL A 486 ALA A 506 GLU A 525 MET A 529 ILE A 532 ALA A 634	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None None	0.58A	1opjA-4k33A: 25.3	1opjA-4k33A: 37.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 VAL A 54 ALA A 67 GLU A 85 MET A 89 VAL A 99 THR A 123 LEU A 180	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None None None SIN A 401 ( 4.5A)	0.76A	1opjA-4o38A: 19.4	1opjA-4o38A: 26.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 386 VAL A 394 ALA A 407 GLU A 428 LEU A 511 ALA A 521	PZW A 801 (-3.9A) PZW A 801 (-4.6A) PZW A 801 (-3.5A) None PZW A 801 (-4.8A) PZW A 801 ( 4.6A)	0.73A	1opjA-4q9zA: 15.0	1opjA-4q9zA: 26.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818 ASP A 829	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-3.6A) None P30 A1001 (-4.6A) None	0.61A	1opjA-4rt7A: 28.0	1opjA-4rt7A: 31.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 VAL A 22 VAL A 65 THR A 81 LEU A 136 ALA A 146	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None	0.69A	1opjA-4ueuA: 32.3	1opjA-4ueuA: 62.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	VAL A 22 ALA A 35 VAL A 65 THR A 81 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) None None	0.67A	1opjA-4ueuA: 32.3	1opjA-4ueuA: 62.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	VAL A 22 ALA A 35 VAL A 65 THR A 81 LEU A 136 ALA A 146	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None	0.62A	1opjA-4ueuA: 32.3	1opjA-4ueuA: 62.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 VAL A 201 ALA A 214 GLU A 235 VAL A 248 LEU A 321	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None None ANW A 601 (-4.9A)	0.76A	1opjA-4wboA: 21.6	1opjA-4wboA: 23.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 MET A 94 VAL A 104 PHE A 128 LEU A 183	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-4.8A) KSA A 405 (-4.6A)	0.57A	1opjA-4wsqA: 22.3	1opjA-4wsqA: 23.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 473 VAL A 481 ALA A 501 GLU A 520 MET A 524 ILE A 527 ALA A 629	40M A1002 ( 4.6A) 40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-3.8A) None 40M A1002 (-3.0A)	0.63A	1opjA-4xcuA: 31.0	1opjA-4xcuA: 38.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 473 VAL A 481 ALA A 501 GLU A 520 MET A 524 LEU A 619 ALA A 629	40M A1002 ( 4.6A) 40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-3.8A) 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.51A	1opjA-4xcuA: 31.0	1opjA-4xcuA: 38.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	7	LEU B 267 VAL B 275 ILE B 312 VAL B 318 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) None 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.88A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.80A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.64A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 VAL A 624 GLU A 661 VAL A 675 LEU A 818 ASP A 829	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.1A) None P30 A1001 (-4.3A) None	0.53A	1opjA-4xufA: 33.5	1opjA-4xufA: 37.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818 ASP A 829	P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 (-3.1A) None P30 A1001 (-4.3A) None	0.46A	1opjA-4xufA: 33.5	1opjA-4xufA: 37.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) None 746 A 702 (-3.7A) 746 A 702 (-4.4A)	0.74A	1opjA-4y93A: 30.3	1opjA-4y93A: 29.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 VAL A 64 PHE A 82 LEU A 135 ALA A 145	None	0.70A	1opjA-4yc6A: 21.9	1opjA-4yc6A: 27.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 477 ALA A 488 GLU A 509 THR A 539 LEU A 595 ALA A 605	None 4CV A 801 (-3.5A) None 4CV A 801 (-2.8A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A)	0.71A	1opjA-4yffA: 18.8	1opjA-4yffA: 28.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 GLU A 531 MET A 535 ILE A 538 LEU A 630 ALA A 640	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) None 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.67A	1opjA-5a46A: 30.5	1opjA-5a46A: 35.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 258 ALA A 275 GLU A 290 THR A 325 PHE A 327 LEU A 386	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 ( 3.8A) STU A 601 ( 3.7A) STU A 601 (-3.4A) STU A 601 (-3.9A)	0.67A	1opjA-5e8yA: 6.3	1opjA-5e8yA: 29.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 99 VAL A 107 ALA A 120 PHE A 172 ALA A 233 ASP A 234	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-4.5A) None None	0.52A	1opjA-5eykA: 17.0	1opjA-5eykA: 24.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 99 VAL A 107 ALA A 120 PHE A 172 LEU A 223 ALA A 233	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-4.5A) 5U5 A 401 (-4.7A) None	0.70A	1opjA-5eykA: 17.0	1opjA-5eykA: 24.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 599 VAL A 607 ALA A 625 GLU A 644 MET A 648 VAL A 658 THR A 674 LEU A 825 ASP A 836	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 ( 4.8A) 748 A1001 (-3.2A) 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.58A	1opjA-5grnA: 28.3	1opjA-5grnA: 35.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	LEU A 20 VAL A 28 ALA A 41 GLU A 61 VAL A 74 LEU A 143 ALA A 156	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A)	0.73A	1opjA-5hu3A: 23.0	1opjA-5hu3A: 27.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 57 VAL A 65 ALA A 77 MET A 99 VAL A 109 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None None IDV A 401 (-4.4A)	0.53A	1opjA-5i3oA: 22.2	1opjA-5i3oA: 23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 GLU A 61 MET A 65 PHE A 92 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None 6G2 A 901 (-4.1A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.68A	1opjA-5j5tA: 21.1	1opjA-5j5tA: 24.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 MET A 65 VAL A 74 PHE A 92 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None 6G2 A 901 (-4.1A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.67A	1opjA-5j5tA: 21.1	1opjA-5j5tA: 24.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 647 ALA A 663 THR A 711 PHE A 713 LEU A 765 ASP A 776	None 6P6 A1001 (-3.3A) 6P6 A1001 (-3.5A) 6P6 A1001 ( 4.5A) 6P6 A1001 (-4.5A) None	0.65A	1opjA-5l6oA: 32.8	1opjA-5l6oA: 37.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 897 ALA A 909 GLU A 927 VAL A 940 PHE A 958 LEU A1016	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) None None ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.63A	1opjA-5lpyA: 22.8	1opjA-5lpyA: 28.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 VAL A 32 ALA A 45 THR A 95 LEU A 153 ALA A 163	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) 9WS A 401 (-4.6A) 9WS A 401 ( 4.0A)	0.68A	1opjA-5w5jA: 23.1	1opjA-5w5jA: 28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	6	VAL A 741 ALA A 754 GLU A 774 VAL A 787 LEU A 866 ALA A 876	None CJM A1102 (-3.1A) None None CJM A1102 (-4.4A) CJM A1102 (-3.6A)	0.49A	1opjA-6b3eA: 22.8	1opjA-6b3eA: 15.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 GLU A 925 VAL A 938 PHE A 958 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) None None None ADP A1201 (-4.5A)	0.71A	1opjA-6c7yA: 28.1	1opjA-6c7yA: 14.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	6	LEU U 20 VAL U 28 ALA U 42 VAL U 75 PHE U 93 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.2A)	0.75A	1opjA-6fdyU: 21.7	1opjA-6fdyU: undetectable

[["1OPJ_A_STIA3_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;VAL A  64;PHE A  82;LEU A 133;ALA A 143","None","0.47A","1opjA-1h4lA:16.4","1opjA-1h4lA:24.44"],["1OPJ_A_STIA3_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;GLU A 236;MET A 240;VAL A 249;THR A 266;LEU A 321","None","0.56A","1opjA-1k9aA:30.9","1opjA-1k9aA:30.26"],["1OPJ_A_STIA3_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;GLU A 236;MET A 240;VAL A 249;THR A 266","None","0.56A","1opjA-1k9aA:30.9","1opjA-1k9aA:30.26"],["1OPJ_A_STIA3_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.67A","1opjA-1opkA:37.3","1opjA-1opkA:58.99"],["1OPJ_A_STIA3_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.60A","1opjA-1opkA:37.3","1opjA-1opkA:58.99"],["1OPJ_A_STIA3_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818","None","0.67A","1opjA-1rjbA:32.5","1opjA-1rjbA:35.85"],["1OPJ_A_STIA3_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"LEU A 595;VAL A 603;ALA A 621;GLU A 640;VAL A 654;THR A 670;LEU A 799;ASP A 810","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-4.3A);STI A   3 (-3.2A);STI A   3 (-4.4A);STI A   3 (-3.9A)","0.55A","1opjA-1t46A:34.0","1opjA-1t46A:36.59"],["1OPJ_A_STIA3_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",7,"LEU A 344;VAL A 352;ALA A 367;GLU A 386;MET A 390;VAL A 399;LEU A 468","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);None;None;None;STU A 100 (-4.5A)","0.60A","1opjA-1u59A:29.8","1opjA-1u59A:38.57"],["1OPJ_A_STIA3_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",6,"LEU A  15;VAL A  23;ALA A  36;GLU A  55;VAL A  68;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);None;HYM A 400 (-4.8A);HYM A 400 (-4.5A)","0.74A","1opjA-1zltA:20.9","1opjA-1zltA:24.84"],["1OPJ_A_STIA3_1","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",7,"LEU A  26;VAL A  34;ALA A  47;GLU A  65;PHE A 100;LEU A 155;ASP A 166","STU A1301 (-4.2A);STU A1301 (-4.8A);STU A1301 (-3.6A);None;STU A1301 (-4.5A);STU A1301 ( 4.8A);None","0.72A","1opjA-2bujA:22.7","1opjA-2bujA:23.88"],["1OPJ_A_STIA3_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;VAL X  25;ALA X  37;GLU X  54;MET X  58;VAL X  67;THR X  82;LEU X 137;ALA X 147","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 ( 4.4A);None;None;STU X 902 (-4.1A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.66A","1opjA-2dq7X:31.7","1opjA-2dq7X:44.22"],["1OPJ_A_STIA3_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"LEU A 162;VAL A 170;ALA A 184;GLU A 201;ILE A 208;ALA A 319","None","0.59A","1opjA-2eu9A:13.7","1opjA-2eu9A:23.18"],["1OPJ_A_STIA3_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"LEU A 162;VAL A 170;ALA A 184;GLU A 201;VAL A 220;LEU A 290;ALA A 319","None","0.56A","1opjA-2eu9A:13.7","1opjA-2eu9A:23.18"],["1OPJ_A_STIA3_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;VAL A 323;THR A 338;LEU A 393;ALA A 403","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 (-3.1A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.85A","1opjA-2h8hA:29.7","1opjA-2h8hA:28.23"],["1OPJ_A_STIA3_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;VAL A 323;THR A 338;PHE A 340","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-4.2A)","0.67A","1opjA-2hckA:29.4","1opjA-2hckA:30.42"],["1OPJ_A_STIA3_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;ALA A 271;MET A 292;VAL A 301;THR A 316;PHE A 318;ALA A 381;ASP A 382","1BM A 499 ( 3.7A);1BM A 499 (-3.6A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A);1BM A 499 ( 3.7A);1BM A 499 (-4.4A)","0.89A","1opjA-2hk5A:26.5","1opjA-2hk5A:46.83"],["1OPJ_A_STIA3_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;GLU A 288;MET A 292;VAL A 301;THR A 316;PHE A 318","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A)","0.63A","1opjA-2hk5A:26.5","1opjA-2hk5A:46.83"],["1OPJ_A_STIA3_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;VAL A 259;ALA A 271;MET A 292;VAL A 301;THR A 316;PHE A 318;LEU A 371;ALA A 381","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 ( 3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.88A","1opjA-2hk5A:26.5","1opjA-2hk5A:46.83"],["1OPJ_A_STIA3_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"GLU A 286;MET A 290;ILE A 293;VAL A 299;THR A 315;PHE A 317;ALA A 380;ASP A 381","GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.75A","1opjA-2hz0A:34.5","1opjA-2hz0A:97.45"],["1OPJ_A_STIA3_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"LEU A 248;VAL A 256;ALA A 269;GLU A 286;MET A 290;ILE A 293;VAL A 299;THR A 315;PHE A 317;ALA A 380","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);GIN A 600 (-3.1A)","0.62A","1opjA-2hz0A:34.5","1opjA-2hz0A:97.45"],["1OPJ_A_STIA3_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"LEU A 248;VAL A 256;ALA A 269;GLU A 286;MET A 290;VAL A 299;THR A 315;PHE A 317;LEU A 370;ALA A 380","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.54A","1opjA-2hz0A:34.5","1opjA-2hz0A:97.45"],["1OPJ_A_STIA3_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"VAL A 436;ALA A 452;GLU A 471;MET A 475;VAL A 484;LEU A 553","4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 ( 4.6A);None;None;4ST A1687 (-4.4A)","0.65A","1opjA-2j0jA:31.6","1opjA-2j0jA:20.72"],["1OPJ_A_STIA3_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;GLU A  51;VAL A  64;PHE A  82;LEU A 134;ALA A 144","None","0.64A","1opjA-2jgzA:16.3","1opjA-2jgzA:28.12"],["1OPJ_A_STIA3_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",10,"LEU A 251;VAL A 259;ALA A 271;GLU A 288;MET A 292;VAL A 301;THR A 316;LEU A 371;ALA A 381;ASP A 382","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A)","0.66A","1opjA-2og8A:26.1","1opjA-2og8A:45.30"],["1OPJ_A_STIA3_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;ALA A 614;GLU A 633;MET A 637;VAL A 647;THR A 663;ASP A 796","None","0.92A","1opjA-2ogvA:22.0","1opjA-2ogvA:38.24"],["1OPJ_A_STIA3_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;GLU A 633;MET A 637;VAL A 647;THR A 663;LEU A 785","None","0.85A","1opjA-2ogvA:22.0","1opjA-2ogvA:38.24"],["1OPJ_A_STIA3_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 487;VAL A 495;ALA A 515;GLU A 534;MET A 538;ILE A 541;LEU A 633;ALA A 643","None","0.60A","1opjA-2psqA:31.3","1opjA-2psqA:35.00"],["1OPJ_A_STIA3_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;THR A 265;PHE A 267;LEU A 328;ALA A 338","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 (-4.3A);ADE A 488 (-4.3A);ADE A 488 (-4.4A);None","0.69A","1opjA-2qluA:24.2","1opjA-2qluA:24.23"],["1OPJ_A_STIA3_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;ALA A 749;VAL A 781;THR A 796;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.0A);GW7 A   1 (-4.2A)","0.72A","1opjA-2r4bA:28.8","1opjA-2r4bA:36.56"],["1OPJ_A_STIA3_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"LEU A  68;VAL A  76;ALA A  92;VAL A 125;PHE A 143;LEU A 194","STU A   1 (-3.8A);None;STU A   1 (-3.3A);None;STU A   1 (-4.6A);STU A   1 (-4.6A)","0.51A","1opjA-2z7rA:21.2","1opjA-2z7rA:26.20"],["1OPJ_A_STIA3_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.51A","1opjA-2z8cA:28.8","1opjA-2z8cA:38.98"],["1OPJ_A_STIA3_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;VAL A 303;THR A 319;PHE A 321;ALA A 384;ASP A 385","None","0.73A","1opjA-2zv7A:25.4","1opjA-2zv7A:46.08"],["1OPJ_A_STIA3_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;VAL A 303;THR A 319;PHE A 321;LEU A 374;ALA A 384","None","0.87A","1opjA-2zv7A:25.4","1opjA-2zv7A:46.08"],["1OPJ_A_STIA3_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;ALA A 515;GLU A 534;MET A 538;ILE A 541","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;None","0.64A","1opjA-3b2tA:24.3","1opjA-3b2tA:39.13"],["1OPJ_A_STIA3_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;MET A 538;ILE A 541;LEU A 633;ALA A 643","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;M33 A1996 (-4.5A);None","0.68A","1opjA-3b2tA:24.3","1opjA-3b2tA:39.13"],["1OPJ_A_STIA3_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;GLU A 531;ILE A 538;LEU A 630;ALA A 640","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.63A","1opjA-3c4fA:31.6","1opjA-3c4fA:39.94"],["1OPJ_A_STIA3_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;MET A 535;ILE A 538;LEU A 630;ALA A 640","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);C4F A   1 ( 3.7A);None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.63A","1opjA-3c4fA:31.6","1opjA-3c4fA:39.94"],["1OPJ_A_STIA3_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;GLU A 236;MET A 240;VAL A 249;THR A 266;LEU A 321","None","0.56A","1opjA-3d7uA:26.5","1opjA-3d7uA:44.26"],["1OPJ_A_STIA3_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;GLU A 236;MET A 240;VAL A 249;THR A 266","None","0.56A","1opjA-3d7uA:26.5","1opjA-3d7uA:44.26"],["1OPJ_A_STIA3_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 663;GLU A 682;MET A 686;VAL A 695;PHE A 713;ASP A 776","IHZ A1001 (-3.3A);IHZ A1001 (-3.8A);IHZ A1001 (-3.5A);IHZ A1001 ( 4.9A);None;IHZ A1001 (-4.8A)","0.73A","1opjA-3dkoA:30.2","1opjA-3dkoA:35.29"],["1OPJ_A_STIA3_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 647;ALA A 663;GLU A 682;MET A 686;VAL A 695;PHE A 713","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 (-3.8A);IHZ A1001 (-3.5A);IHZ A1001 ( 4.9A);None","0.68A","1opjA-3dkoA:30.2","1opjA-3dkoA:35.29"],["1OPJ_A_STIA3_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 833;VAL A 841;ALA A 859;GLU A 878;ILE A 885;VAL A 892;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.7A);None","0.70A","1opjA-3hngA:32.8","1opjA-3hngA:34.03"],["1OPJ_A_STIA3_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 841;ALA A 859;GLU A 878;ILE A 885;VAL A 892;LEU A1029;ASP A1040","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.7A);None;None","0.81A","1opjA-3hngA:32.8","1opjA-3hngA:34.03"],["1OPJ_A_STIA3_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"VAL A  67;ALA A  80;MET A 104;VAL A 113;ALA A 192;ASP A 193","None","0.63A","1opjA-3iecA:22.4","1opjA-3iecA:25.66"],["1OPJ_A_STIA3_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"VAL A  67;ALA A  80;MET A 104;VAL A 113;LEU A 182;ALA A 192","None","0.73A","1opjA-3iecA:22.4","1opjA-3iecA:25.66"],["1OPJ_A_STIA3_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",7,"VAL A  33;ALA A  46;GLU A  66;VAL A  79;PHE A 105;LEU A 156;ALA A 166","None","0.64A","1opjA-3mi9A:22.6","1opjA-3mi9A:26.08"],["1OPJ_A_STIA3_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",6,"LEU A  49;VAL A  57;ALA A  70;GLU A  91;VAL A 104;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;XFE A 351 (-4.6A)","0.74A","1opjA-3mvjA:20.6","1opjA-3mvjA:24.93"],["1OPJ_A_STIA3_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",7,"VAL A  37;ALA A  49;GLU A  69;VAL A  82;PHE A 100;LEU A 151;ALA A 161","ADP A 314 (-4.0A);ADP A 314 (-3.5A);None;None;ADP A 314 ( 4.3A);ADP A 314 (-4.6A);None","0.78A","1opjA-3nizA:22.5","1opjA-3nizA:26.65"],["1OPJ_A_STIA3_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"LEU A  88;VAL A  96;ALA A 109;GLU A 130;MET A 134;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);None;None","0.57A","1opjA-3nuuA:22.5","1opjA-3nuuA:25.65"],["1OPJ_A_STIA3_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",7,"LEU A 423;VAL A 431;ALA A 443;MET A 464;VAL A 473;THR A 489;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;PP2 A   1 (-3.3A);PP2 A   1 (-4.6A)","0.66A","1opjA-3sxsA:31.0","1opjA-3sxsA:41.78"],["1OPJ_A_STIA3_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;GLU A 531;MET A 535;ILE A 538;LEU A 630;ALA A 640","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);None;07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.62A","1opjA-3tt0A:30.5","1opjA-3tt0A:34.38"],["1OPJ_A_STIA3_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;LEU A1035","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;4TT A2001 (-4.5A);4TT A2001 (-4.8A)","0.68A","1opjA-3vidA:29.9","1opjA-3vidA:33.33"],["1OPJ_A_STIA3_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;VAL A 848;ALA A 866;ILE A 892;VAL A 899;PHE A 918;LEU A1035;ASP A1046","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;4TT A2001 (-4.5A);4TT A2001 (-4.8A);None","0.77A","1opjA-3vidA:29.9","1opjA-3vidA:33.33"],["1OPJ_A_STIA3_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;VAL A 899;PHE A 918;LEU A1035","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.7A);None;LEV A1201 (-4.7A);LEV A1201 (-4.8A)","0.62A","1opjA-3wzdA:30.8","1opjA-3wzdA:37.69"],["1OPJ_A_STIA3_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;ILE A 892;VAL A 899;PHE A 918;LEU A1035","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;None;LEV A1201 (-4.7A);LEV A1201 (-4.8A)","0.64A","1opjA-3wzdA:30.8","1opjA-3wzdA:37.69"],["1OPJ_A_STIA3_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;GLU A  50;VAL A  63;PHE A  81;LEU A 132","38R A 350 ( 4.8A);38R A 350 (-3.4A);38R A 350 ( 4.8A);38R A 350 ( 4.9A);38R A 350 (-4.2A);38R A 350 (-4.3A)","0.49A","1opjA-3zduA:22.3","1opjA-3zduA:28.17"],["1OPJ_A_STIA3_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 633;ALA A 649;GLU A 668;MET A 672;THR A 697;PHE A 699","None","0.75A","1opjA-3zfxA:31.5","1opjA-3zfxA:40.20"],["1OPJ_A_STIA3_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;LEU A1035;ASP A1046","B49 A2000 (-3.7A);B49 A2000 (-3.5A);None;None;B49 A2000 ( 4.6A);B49 A2000 (-4.4A);B49 A2000 (-4.5A);None","0.69A","1opjA-4agdA:32.4","1opjA-4agdA:35.01"],["1OPJ_A_STIA3_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;LEU A1035","B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);None;None;B49 A2000 ( 4.6A);B49 A2000 (-4.4A);B49 A2000 (-4.5A)","0.68A","1opjA-4agdA:32.4","1opjA-4agdA:35.01"],["1OPJ_A_STIA3_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"LEU A  42;VAL A  50;ALA A  63;VAL A  94;LEU A 164;ALA A 174","XZN A1317 (-3.6A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.61A","1opjA-4bc6A:21.2","1opjA-4bc6A:28.93"],["1OPJ_A_STIA3_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"LEU A  42;VAL A  50;ALA A  63;VAL A  94;PHE A 112;ALA A 174","XZN A1317 (-3.6A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.5A);XZN A1317 ( 4.3A)","0.50A","1opjA-4bc6A:21.2","1opjA-4bc6A:28.93"],["1OPJ_A_STIA3_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"LEU A 616;VAL A 624;ALA A 653;GLU A 672;MET A 676;THR A 701;LEU A 773;ALA A 783;ASP A 784","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.6A);DI1 A1000 (-4.5A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A)","0.70A","1opjA-4ckrA:32.1","1opjA-4ckrA:37.27"],["1OPJ_A_STIA3_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 663;VAL A 671;ALA A 684;GLU A 705;VAL A 721;LEU A 789;ALA A 799","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.69A","1opjA-4crsA:15.9","1opjA-4crsA:26.05"],["1OPJ_A_STIA3_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;VAL A 863;ALA A 880;GLU A 898;VAL A 911;LEU A 983","IZA A2001 (-3.7A);None;IZA A2001 (-3.4A);None;None;IZA A2001 ( 4.7A)","0.70A","1opjA-4gl9A:19.7","1opjA-4gl9A:34.70"],["1OPJ_A_STIA3_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"LEU A 828;VAL A 836;ALA A 853;GLU A 871;VAL A 884;LEU A 956;ALA A 966","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);None;None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.58A","1opjA-4hviA:29.5","1opjA-4hviA:35.40"],["1OPJ_A_STIA3_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;ALA A 506;GLU A 525;MET A 529;ILE A 532;LEU A 624;ALA A 634","ACP A 801 (-3.8A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;ACP A 801 (-4.4A);None","0.75A","1opjA-4k33A:25.3","1opjA-4k33A:37.91"],["1OPJ_A_STIA3_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;VAL A 486;ALA A 506;GLU A 525;MET A 529;ILE A 532;ALA A 634","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;None","0.58A","1opjA-4k33A:25.3","1opjA-4k33A:37.91"],["1OPJ_A_STIA3_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;VAL A  54;ALA A  67;GLU A  85;MET A  89;VAL A  99;THR A 123;LEU A 180","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;None;None;SIN A 401 ( 4.5A)","0.76A","1opjA-4o38A:19.4","1opjA-4o38A:26.19"],["1OPJ_A_STIA3_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 386;VAL A 394;ALA A 407;GLU A 428;LEU A 511;ALA A 521","PZW A 801 (-3.9A);PZW A 801 (-4.6A);PZW A 801 (-3.5A);None;PZW A 801 (-4.8A);PZW A 801 ( 4.6A)","0.73A","1opjA-4q9zA:15.0","1opjA-4q9zA:26.33"],["1OPJ_A_STIA3_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818;ASP A 829","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-3.6A);None;P30 A1001 (-4.6A);None","0.61A","1opjA-4rt7A:28.0","1opjA-4rt7A:31.73"],["1OPJ_A_STIA3_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;VAL A  22;VAL A  65;THR A  81;LEU A 136;ALA A 146","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None","0.69A","1opjA-4ueuA:32.3","1opjA-4ueuA:62.80"],["1OPJ_A_STIA3_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"VAL A  22;ALA A  35;VAL A  65;THR A  81;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);None;None","0.67A","1opjA-4ueuA:32.3","1opjA-4ueuA:62.80"],["1OPJ_A_STIA3_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"VAL A  22;ALA A  35;VAL A  65;THR A  81;LEU A 136;ALA A 146","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None","0.62A","1opjA-4ueuA:32.3","1opjA-4ueuA:62.80"],["1OPJ_A_STIA3_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;VAL A 201;ALA A 214;GLU A 235;VAL A 248;LEU A 321","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;None;ANW A 601 (-4.9A)","0.76A","1opjA-4wboA:21.6","1opjA-4wboA:23.59"],["1OPJ_A_STIA3_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;MET A  94;VAL A 104;PHE A 128;LEU A 183","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-4.8A);KSA A 405 (-4.6A)","0.57A","1opjA-4wsqA:22.3","1opjA-4wsqA:23.21"],["1OPJ_A_STIA3_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"LEU A 473;VAL A 481;ALA A 501;GLU A 520;MET A 524;ILE A 527;ALA A 629","40M A1002 ( 4.6A);40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-3.8A);None;40M A1002 (-3.0A)","0.63A","1opjA-4xcuA:31.0","1opjA-4xcuA:38.83"],["1OPJ_A_STIA3_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"LEU A 473;VAL A 481;ALA A 501;GLU A 520;MET A 524;LEU A 619;ALA A 629","40M A1002 ( 4.6A);40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-3.8A);40M A1002 (-4.5A);40M A1002 (-3.0A)","0.51A","1opjA-4xcuA:31.0","1opjA-4xcuA:38.83"],["1OPJ_A_STIA3_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",7,"LEU B 267;VAL B 275;ILE B 312;VAL B 318;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);None;1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.88A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_A_STIA3_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.80A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_A_STIA3_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.64A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_A_STIA3_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;VAL A 624;GLU A 661;VAL A 675;LEU A 818;ASP A 829","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.1A);None;P30 A1001 (-4.3A);None","0.53A","1opjA-4xufA:33.5","1opjA-4xufA:37.42"],["1OPJ_A_STIA3_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818;ASP A 829","P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 (-3.1A);None;P30 A1001 (-4.3A);None","0.46A","1opjA-4xufA:33.5","1opjA-4xufA:37.42"],["1OPJ_A_STIA3_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);None;746 A 702 (-3.7A);746 A 702 (-4.4A)","0.74A","1opjA-4y93A:30.3","1opjA-4y93A:29.04"],["1OPJ_A_STIA3_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;VAL A  64;PHE A  82;LEU A 135;ALA A 145","None","0.70A","1opjA-4yc6A:21.9","1opjA-4yc6A:27.56"],["1OPJ_A_STIA3_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"VAL A 477;ALA A 488;GLU A 509;THR A 539;LEU A 595;ALA A 605","None;4CV A 801 (-3.5A);None;4CV A 801 (-2.8A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A)","0.71A","1opjA-4yffA:18.8","1opjA-4yffA:28.88"],["1OPJ_A_STIA3_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;GLU A 531;MET A 535;ILE A 538;LEU A 630;ALA A 640","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);None;38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.67A","1opjA-5a46A:30.5","1opjA-5a46A:35.49"],["1OPJ_A_STIA3_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"VAL A 258;ALA A 275;GLU A 290;THR A 325;PHE A 327;LEU A 386","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 ( 3.8A);STU A 601 ( 3.7A);STU A 601 (-3.4A);STU A 601 (-3.9A)","0.67A","1opjA-5e8yA:6.3","1opjA-5e8yA:29.50"],["1OPJ_A_STIA3_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"LEU A  99;VAL A 107;ALA A 120;PHE A 172;ALA A 233;ASP A 234","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-4.5A);None;None","0.52A","1opjA-5eykA:17.0","1opjA-5eykA:24.84"],["1OPJ_A_STIA3_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"LEU A  99;VAL A 107;ALA A 120;PHE A 172;LEU A 223;ALA A 233","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-4.5A);5U5 A 401 (-4.7A);None","0.70A","1opjA-5eykA:17.0","1opjA-5eykA:24.84"],["1OPJ_A_STIA3_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",9,"LEU A 599;VAL A 607;ALA A 625;GLU A 644;MET A 648;VAL A 658;THR A 674;LEU A 825;ASP A 836","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 ( 4.8A);748 A1001 (-3.2A);748 A1001 (-4.3A);748 A1001 (-4.8A)","0.58A","1opjA-5grnA:28.3","1opjA-5grnA:35.46"],["1OPJ_A_STIA3_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"LEU A  20;VAL A  28;ALA A  41;GLU A  61;VAL A  74;LEU A 143;ALA A 156","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A)","0.73A","1opjA-5hu3A:23.0","1opjA-5hu3A:27.36"],["1OPJ_A_STIA3_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  57;VAL A  65;ALA A  77;MET A  99;VAL A 109;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;None;IDV A 401 (-4.4A)","0.53A","1opjA-5i3oA:22.2","1opjA-5i3oA:23.10"],["1OPJ_A_STIA3_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;GLU A  61;MET A  65;PHE A  92;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;6G2 A 901 (-4.1A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.68A","1opjA-5j5tA:21.1","1opjA-5j5tA:24.38"],["1OPJ_A_STIA3_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;MET A  65;VAL A  74;PHE A  92;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;6G2 A 901 (-4.1A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.67A","1opjA-5j5tA:21.1","1opjA-5j5tA:24.38"],["1OPJ_A_STIA3_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"VAL A 647;ALA A 663;THR A 711;PHE A 713;LEU A 765;ASP A 776","None;6P6 A1001 (-3.3A);6P6 A1001 (-3.5A);6P6 A1001 ( 4.5A);6P6 A1001 (-4.5A);None","0.65A","1opjA-5l6oA:32.8","1opjA-5l6oA:37.95"],["1OPJ_A_STIA3_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"VAL A 897;ALA A 909;GLU A 927;VAL A 940;PHE A 958;LEU A1016","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);None;None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.63A","1opjA-5lpyA:22.8","1opjA-5lpyA:28.75"],["1OPJ_A_STIA3_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;VAL A  32;ALA A  45;THR A  95;LEU A 153;ALA A 163","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);9WS A 401 (-4.6A);9WS A 401 ( 4.0A)","0.68A","1opjA-5w5jA:23.1","1opjA-5w5jA:28.10"],["1OPJ_A_STIA3_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",6,"VAL A 741;ALA A 754;GLU A 774;VAL A 787;LEU A 866;ALA A 876","None;CJM A1102 (-3.1A);None;None;CJM A1102 (-4.4A);CJM A1102 (-3.6A)","0.49A","1opjA-6b3eA:22.8","1opjA-6b3eA:15.95"],["1OPJ_A_STIA3_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;GLU A 925;VAL A 938;PHE A 958;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);None;None;None;ADP A1201 (-4.5A)","0.71A","1opjA-6c7yA:28.1","1opjA-6c7yA:14.02"],["1OPJ_A_STIA3_1","6fdy","-","-","no annotation",6,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;PHE U  93;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.2A)","0.75A","1opjA-6fdyU:21.7","1opjA-6fdyU:undetectable"]]